Obesity has also been demonstrated to reduce the effectiveness of adjuvant aromatase inhibitors in women with hormone receptor-positive breast cancer because it increases the activity of peripheral aromatase inhibitors [98]. The gene discussed is CYP19A1; the disease is obesity due to melanocortin 4 receptor deficiency.